McGill-led ALS study benchmarks 303 research antibodies
Published by BriefDash · · Toronto
A McGill-led team’s ALS antibody study reached final publication in eLife on November 3, following reviewed preprints in June and October. Researchers tested 303 antibodies targeting 33 proteins associated with amyotrophic lateral sclerosis, using laboratory controls to assess performance. The work provides a resource for choosing experimental tools; it does not demonstrate a treatment or establish clinical benefits.
Why it matters
Antibody performance depends on the experimental application, making validation useful for reproducible research.
Source dated November 3, 2026 · Ayoubi and colleagues / eLife ↗
Source: Ayoubi and colleagues, eLife 15:e111349, final version published November 3, 2026. Independently written BriefDash summary.
Independent factual brief. Original BriefDash illustration. Automated preparation and publication; editorial policy ↗
Suggest a correction ↗